Arcus Biosciences RCUS
NYSE RCUS
$29.65 -0.48 (-1.59%)
As of: Sep 4, 2026 · 3:59 PM EDT

Arcus Biosciences (RCUS) Operating Income Growth (3y) (2020 - 2026)

Analysis

Arcus Biosciences (RCUS) Operating Income Growth (3y) (2020 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 6.70%
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 8.36%
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 89.72%
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 24.14%
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 44.54%
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 44.34%
8 Royalty Pharma 28.45 Bn 27.61 Bn - -18.82%
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 81.27%
10 Arcus Biosciences 3.74 Bn 3.04 Bn - -4.97%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -4.97%
Mar 31, 2026 -15.93%
Dec 31, 2025 -15.49%
Sep 30, 2025 -26.59%
Jun 30, 2025 51.24%
Mar 31, 2025 -22.11%
Dec 31, 2024 -33.26%
Sep 30, 2024 -10.35%
Jun 30, 2024 -11.66%
Mar 31, 2024 39.64%
Dec 31, 2023 -20.68%
Sep 30, 2023 -276.91%
Jun 30, 2023 -22.30%
Mar 31, 2023 -44.67%
Dec 31, 2022 -61.62%
Sep 30, 2022 -44.40%
Jun 30, 2022 -33.26%
Mar 31, 2022 -52.82%
Dec 31, 2021 183.73%
Sep 30, 2021 -85.99%